Trans-arterial chemo-embolization (TACE), with either lipiodol (traditional TACE) or drug-eluting microspheres (precision TACE, pTACE) in the treatment of hepatocellular carcinoma: efficacy and safety results from a large mono-institutional analysis by Scartozzi, Mario et al.
RESEARCH Open Access
Trans-arterial chemo-embolization (TACE), with
either lipiodol (traditional TACE) or drug-eluting
microspheres (precision TACE, pTACE) in the
treatment of hepatocellular carcinoma: efficacy
and safety results from a large mono-institutional
analysis
Mario Scartozzi
1, Gianluca Svegliati Baroni
2, Luca Faloppi
3, Marzia Di Pietro Paolo
4, Chiara Pierantoni
1,
Roberto Candelari
5, Rossana Berardi
1, Stefania Antognoli
1, Cinzia Mincarelli
5, Andrea Risaliti
6, Cristina Marmorale
7,
Ettore Antico
5, Antonio Benedetti
2, Stefano Cascinu
1*
Abstract
More data about TACE and pTACE seem necessary to better define the global treatment strategy for HCC. Aim of
our analysis was to evaluate the role of TACE, either with lipiodol (traditional) or drug-eluting microspheres in
terms of response rate (RR), time to progression (TTP), overall survival (OS) and toxicity in HCC.
Patients with HCC undergoing traditional TACE or pTACE (either alone or in combination with other treatment
options) were eligible
One hundred and fifty patients were analyzed. In the global patient population median OS was 46 months for
lipiodol TACE and 19 months for pTACE (p < 0.0001), TTP was 30 months versus 16 months for patients receiving
TACE or pTACE respectively (p = 0.003). These results were confirmed also among the group of patients who
received exclusive TACE or pTACE. Neither RR nor toxicity was different between TACE or pTACE.
At multivariate analysis, age, the Okuda stage, type of TACE and number of TACE proved to be independent prog-
nostic factors influencing overall survival.
In our experience, lipiodol TACE showed a better OS and TTP over pTACE, without difference in toxicity profile and
RR. Among the staging systems analyzed only the Okuda stage seemed able to reliably predict patients outcome.
Background
Hepatocellular carcinoma (HCC) represents the com-
monest primary cancer of the liver. Incidence is increas-
ing and HCC has risen to become the 5th commonest
malignancy worldwide and the third leading cause of
cancer related death, exceeded only by cancers of the
lung and stomach [1,2].
Surgery is the only potentially curative treatment for
HCC. In carefully selected patients, resection and
transplantation allow in fact a survival ranging from
60% to 70%, and should be considered as the preferred
treatment options in early-stage disease with the assess-
ment of hepatic functional reserve being essential for
treatment planning [3].
The percutaneous treatment for HCC, percutaneous
alcohol injection (PEI) and the radiofrequency thermal
ablation (RF), are an alternative to surgery in patients
with early stage disease who are not candidates to resec-
tion or transplantation [4,5].
The majority of patients in Western countries presents
an intermediate or advanced stage at diagnosis. These
patients are therefore candidates treatment including
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systemic treatments including chemotherapy, immu-
n o t h e r a p ya n dh o r m o n a lt h e r a p y[ 6 ] .O n l yr e c e n t l y ,a
molecular targeted drug, Sorafenib, has been proved
effective in these patients [7-9].
TACE represents a crucial treatment option for HCC,
however comparative assessment of clinical findings
resulted often hampered by the considerable variability
in patients selection criteria and modalities of execution
of therapy [10-12]. Nonetheless meta-analyses of clinical
trials suggested a favorable impact of this procedure on
survival [13,14] and the reports of Lo and Llovet inde-
pendently showed a significant increase in survival in
patients treated with TACE compared to control group
[15,16].
In the last few years pTACE (precision TACE with
drug-eluting microspheres) presented as a possible
further improvement in the treatment of HCC, but few
data are available about its role, particularly in compari-
son with traditional TACE, for the global treatment
strategy in HCC patients.
Primary aim of our analysis was to evaluate the role of
transarterial chemoembolization, either with lipiodol
(traditional TACE) or drug-eluting microspheres (preci-
sion TACE, pTACE), in terms of response rate (RR),
time to progression (TTP) and overall survival (OS), in
patients with advanced HCC.
Secondary aim of the study was to evaluate the role of
pTACE compared to TACE and toxicity deriving from
treatment.
Materials and methods
Patients selection
We have retrospectively analyzed a population of HCC
patients, treated with TACE (lipiodol or drug-eluting
microspheres) from 2002 to 2009, at our institution.
The study included all patients consecutively treated
with TACE (in our institution, patients were treated
with TACE with lipiodol from 2002 until 2006 and with
TACE with microspheres from 2007 to 2009).
All patients studied were suffering by liver cirrhosis,
70% on viral etiology (HBV and HCV chronic hepatitis),
15% on toxic etiology (alcohol), 15% caused by genetic
and metabolic diseases.
Patients were divided into two groups. The first group
included patients who received, as the sole treatment for
HCC, either traditional TACE (selective TACE with infu-
sion of chemotherapeutic agents associated with lipiodol,
without the use of microspheres) or pTACE (superselec-
tive TACE with drug-eluting microspheres). The second
group included patients who received TACE or pTACE in
addiction to other treatments, such as liver resection, liver
transplantation, alcoholic or laser ablation, radiofrequency
thermal ablation, systemic therapies. Furthermore, we
analyzed, separately the group of patients treated with tra-
ditional TACE or pTACE.
Patients were classified according to ECOG perfor-
mance status and were staged using different staging
systems to assess patients general clinical condition,
extent of disease and liver function: TNM, Child-Pugh,
CLIP, BCLC, Okuda, JIS, MELD, MELD-Na.
For each patient the dose of chemotherapy of each
treatment were recorded, and the dose to the first treat-
ment and the cumulative dose were assessed. Patients
were then divided into two groups (high and low dose)
in relation to the median dose of drug.
Clinical outcome evaluation and statistical analysis
Treatment response was assessed through CT and MRI,
a-FP assay, performed after one month of treatment
and then every 3 months, according to the new RECIST
criteria (New Response Evaluation Criteria in Solid
Tumors 1.1). Radiological images were reviewed in dou-
ble-blind by two radiologists.
The distribution curves of survival and time to progres-
sion were estimated using the Kaplan-Meier method.
Overall survival (OS) was calculated as the time interval
between the date of radiological or histological diagnosis
of HCC and the date of death or last follow-up. The time
to progression (TTP) was calculated as the time interval
between the date of the traditional TACE or pTACE and
the date of progression or last follow-up. Treatment toxi-
city was evaluated according to NCI-CTC 3.0 (National
Cancer Institute - Common Toxicity Criteria 3.0). Toxi-
city profiles were grouped by severity (G1-G2 vs. G3-G4)
and the time (early <1 week vs delayed >1 week)
The clinical variables analyzed were: gender (male vs.
female), age (≤69 years vs. >69 years), ECOG performance
status (0-1 vs. 2-3), TNM stage (I-IIIB vs IIIC - IV), the
Child-Pugh score (A vs. B), the CLIP stage (0-1 vs >1),
BCLC stage (A vs. B-C), Okuda stage (I vs. II vs. III), stage
JIS (0-1 vs >1), the MELD score (≤10 vs. 11-15 vs. >15), the
MELD-Na score (≤10 vs. 11-15 vs. >15), exclusive TACE
vs. TACE + other treatments, thet y p eo fT A C E( t r a d i t i o n a l
TACE with lipiodol vs. pTACE with drug-eluting micro-
spheres) and the number of re-treatments (1 vs. 2 vs. ≥3).
The association between variables was estimated using
the chi-square test.
The Cox multiple regression analysis was used for
those variables that were found significant at the uni-
variate analysis.
Any differences between the groups were considered
significant if the significance level was less than 0.05.
Results
One hundred and fifty patients were available for our
analysis: 122 (81%) males and 28 (19%) females. Median
age was 69 years (range 49-89) (Table 1).
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as the only therapeutic approach, while 68 patients
(45%) received also other treatments.
In the group of patients treated with TACE only, 50
(61%) underwent traditional TACE, while 32 (39%)
received pTACE with microspheres.
All groups of patients showed similar clinical charac-
teristics according to all staging systems used (Table 2).
In the whole group, median survival was 32 months,
while median time to progression was 24 months.
Patients treated with TACE only showed a median sur-
vival of 30 months, compared to 32 months for patients
treated with other treatments in addition to TACE (p =
0.69). The time to progression was 26 months versus 24
months respectively in patients treated with TACE only
and in those treated with other therapies (p = 0.85).
Median overall survival was 46 months for patients
undergoing traditional TACE and 19 months for those
who were treated with pTACE (p < 0.0001) (Figure 1)
and time to progression w a s3 0m o n t h sv e r s u s1 6
months for patients receiving either traditional TACE or
pTACE respectively (p = 0.003) (Figure 2). These results
were confirmed also among the group of patients who
received exclusive traditional TACE or pTACE as the
only treatment approach. In particular median overall
survival was 46 months for patients treated with lipiodol
TACE compared to 14 months for patients treated with
pTACE (p = 0.0002) (Figure 3). Median time to progres-
sion was 32 months for patients treated with traditional
TACE compared to 13 months for patients treated with
pTACE (p = 0.014) (Figure 4).
At the univariate analysis, age (p < 0.0001), Okuda
stage (p = 0.046) (Figure 5), type of TACE (P < 0,0001)
and number of TACE treatments (p = 0.003) were
found to be prognostic factors influencing overall survi-
val. Type of TACE (p = 0.0003) and the number of
TACE treatments (p = 0.004) were also found to be
prognostic factors influencing the time to progression.
At multivariate analysis, age, the Okuda stage, type of
TACE and number of TACE treatments proved to be
independent prognostic factors influencing overall survi-
val (p < 0.0001). Only type and number of TACE treat-
ments proved to be independent prognostic factors
influencing time to progression (p < 0.0001).
Overall response rate for patients treated with lipiodol
TACE or pTACE respectively was: complete response in
17 (20%) and 14 (24%) patients, partial remission in 32
(39%) and 19 (33%) patients, stable disease in 16 (19%)
and 7 (12%) patients, and progressive disease in 18
(22%) and 18 (31%) patients.
No statistically significant differences in terms of objec-
tive response (assessed according to RECIST criteria) was
found between the groups of patients treated with lipio-
dol TACE or pTACE with microspheres (Table 3).
Table 1 Patients characteristics and main results
Patients General
series
TACE
exclusive
TACE non
exclusive
TACE exclusive
lipiodol
TACE exclusive
microspheres
n = 150 n = 82 n = 68 n = 50 n = 32
Median Age (range) 69 (40-89) 72 (41-89) 66 (40-84) 74 (42-89) 68 (41-79)
OS months (range) 32 (3-124) 30 (3-91) 32 (3-124) 46 (3-87) 14 (3-91)
TTP months (range) 24 (1-64) 26 (1-64) 24 (1-52) 32 (1-64) 13 (1-28)
Gender (%)
male 122 (81) 65 (79) 57 (84) 36 (79) 29 (91)
female 28 (19) 17 (21) 11 (16) 14 (21) 3 (9)
Patients undergoing TACE (%)
TACE exclusive 82 (55)
TACE non exclusive 68 (45)
Type of TACE (%)
TACE 87 (58) 50 (61) 37 (54)
pTACE 63 (42) 32 (39) 31 (46)
OS months (Type of TACE)
(range)
TACE 46 (3-124)
pTACE 19 (3-91)
TTP months (Type of TACE)
(range)
TACE 30 (1-64)
pTACE 16 (1-38)
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between the groups of patients treated with lipiodol
TACE or pTACE (Table 4).
In the overall series, 32 (21%) patients underwent a
minimum of 3 TACE treatments, 39 (26%) underwent 2
treatments and 79 (53%) received a single treatment. In
these groups a statistically significant difference was
noted for overall survival (p = 0.003) (Figure 6) and
time to progression (p = 0.0042) (Figure 7). No correla-
tions could be noticed between the number of treat-
ments performed, stage of disease and liver function.
Fifteen (19%) patients who received traditional TACE
or pTACE only were treated with at least 3 TACE ses-
sions and showed a median survival of 74 months, 24
(29%) received 2 treatments with a median survival of
29 months (range 3-43) and 43 (52%) were subjected to
Table 2 Patients sub-groups stratification according to staging systems used in our analysis
Staging systems
Patients General series TACE exclusive TACE non exclusive TACE exclusive lipiodol TACE exclusive microspheres
Score (%) n = 150 n = 82 n = 68 n = 50 n = 32
ECOG 0-1 133 (89) 73 (89) 60 (88) 42 (84) 31 (97)
2-4 17 (11) 9 (11) 8 (12) 8 (16) 1 (3)
TNM 1-3B 130 (87) 72 (88) 58 (85) 44 (88) 28 (87)
3C-4 20 (13) 10 (12) 10 (15) 6 (12) 4 (13)
Child-Pugh A 87 (58) 39 (48) 48 (70) 26 (51) 14 (43)
B 63 (42) 43 (52) 20 (30) 24 (49) 18 (57)
CLIP 0-1 92 (61) 47 (57) 44 (64) 29 (58) 18 (57)
> 1 58 (39) 35 (43) 24 (36) 21 (42) 14 (43)
BCLC A 74 (46) 32 (39) 41 (61) 19 (38) 13 (41)
B-C 76 (54) 50 (61) 27 (39) 31 (62) 19 (59)
Okuda 1 98 (65) 50 (61) 47 (69) 31 (62) 19(60)
2 48 (32) 27 (33) 21 (31) 17 (33) 11 (33)
3 4 (3) 5 (6) 0 (0) 2 (5) 2 (7)
JIS 0-1 79 (52) 37 (45) 41 (60) 24 (49) 13 (40)
> 1 71 (48) 45 (55) 27 (40) 26 (51) 19 (60)
MELD ≤10 101 (67) 53 (65) 49 (72) 32 (64) 21 (67)
11-15 42 (28) 25 (30) 18 (27) 15 (30) 9 (29)
> 15 7 (5) 4 (5) 1 (1) 3 (6) 2 (4)
MELD-Na ≤10 65 (43) 37 (45) 39 (57) 21 (42) 16 (50)
11-15 58 (39) 37 (45) 22 (33) 22 (45) 15 (46)
> 15 27 (18) 8 (10) 7 (10) 7 (13) 1 (4)
Figure 1 Median overall survival for patients undergoing
traditional TACE (—) and for those who were treated with
pTACE (———————) (46 vs 19 months, p < 0.0001).
Figure 2 Median time to progression for patients undergoing
traditional TACE (—) and for those who were treated with
pTACE (———————) (30 vs 16 months, p < 0.003).
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3-87) (p = 0.0286). The difference in time to progression
was not statistically significant (p = 0.057).
In the whole patients population statistically significant
differences were noted in relation to the dose of che-
motherapy administered (< 53 mg or ≥53 mg) at the time
of the first TACE or pTACE, for both median overall sur-
vival (46 months, vs 24 months, p < 0.0001) and time to
progression (30 months vs 17 months, p = 0.0061).
Discussion
Several studies have demonstrated the efficacy of TACE
with lipiodol, for the treatment of HCC. However
comparative assessment of results is often hampered by
the considerable variability in patients selection criteria
and in modalities of treatment administration.
Favorable results on overall survival for treatments
with lipiodol TACE, reported by retrospective studies
were initially questioned by randomized controlled clini-
cal trials with groups of patients treated conservatively
[10-12] with subsequent meta-analyses of previous clini-
cal trials suggesting a favorable impact of this procedure
on survival [13,14].
More recently the reports of Lo and Llovet independently
showed a significant survival improvement for patients trea-
ted with TACE compared to control groups [15,16].
These results are probably attributable to the stringent
criteria for patient selection and to the maintenance of
results over time through repetition of the procedure,
with an average of 2.8 TACE treatment per patient.
In the last years the treatment of pTACE with micro-
spheres is increasingly arguing for the management of
patients with HCC and recent studies have validated the
Figure 3 Median overall survival for patients undergoing
traditional TACE (—) and for those who were treated with
pTACE (———————) (46 vs 14 months, p = 0.0002). Only
patients receiving exclusive TACE were considered.
Figure 4 Median time to progression for patients undergoing
traditional TACE (—) and for those who were treated with
pTACE (———————) (32 vs 13 months, p = 0.014). Only
patients receiving exclusive TACE were considered.
Figure 5 Median overall survival for global patients population
according to the Okuda staging system: Okuda 1(—), Okuda 2
(———————) and Okuda 3 (.........) (33 vs 29 vs 14 months,
p = 0.046).
Table 3 Response rate observed in the global case series
and according to treatment received (lipiodol TACE or
pTACE) (CR = complete remission; PR = partial remission;
SD = stable disease; PD = progressive disease NA = not
available)
Objective response
TACE lipiodol pTACE microspheres Total
CR (%) 17 (20) 14 (24) 31 (22)
PR (%) 32 (39) 19 (33) 51 (36)
SD (%) 16 (19) 7 (12) 23 (15)
PD (%) 18 (22) 18 (31) 36 (27)
NA 81 9
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objective response rate [17].
Two recent trials presented at the American Society of
Clinical Oncology annual Meeting 2009, one retrospec-
tive [18], and one prospective [19] have shown an
advantage in terms of overalls u r v i v a la n do b j e c t i v e
complete responses in favor of pTACE with micro-
spheres for patients with unresectable HCC.
In our experience treatment with microspheres could
not confirm these findings, in particular for overall
survival and time to progression. On the contrary in our
series median overall survival resulted improved in the
group of patients treated with lipiodol TACE compared
to the group of patients treated with microspheres,
while no significant differences were noticed in terms of
response rate.
Although these apparently conflicting results may be
related to the retrospective nature of our study, differ-
ences in the patients population investigated and to
inevitable selection bias, we should note that the sample
Table 4 Main toxicity results for lipiodol TACE and pTACE according to NCI-CTC 3.0 (National Cancer Institute -
Common Toxicity Criteria 3.0).
Toxicity
Total G3 - G4
TACE lipiodol pTACE microspheres TACE lipiodol pTACE microspheres
early late early late early late early late
Hepatic (%)
transaminase 31 (41) 6 (8) 22 (33) 11 (16) 7 (9) - 2 (3) -
g-gt 22 (29) 9 (12) 16 (24) 12 (18) 5 (7) 3 (4) 5 (7) 6 (9)
alkaline phosphatase 8 (11) 4 (5) 7 (10) 7 (10) - - - -
bilirubin 25 (33) 2 (3) 16 (24) 5 (7) 3 (4) 2 (3) 3 (4) -
coagulation - 1 (1) - - - - - -
albumin 7 (9) 2 (3) 3 (4) 1 (1) - - 1 (1) -
Hematologic (%)
leukopenia 4 (5) 2 (3) 2 (3) 4 (6) 1 (1) - 1 (1) 1 (1)
anemia 8 (11) 6 (8) 6 (9) 4 (6) 1 (1) - - -
piastinopenia 22 (29) 6 (8) 21 (31) 11 (16) 1 (1) - 6 (9) 2 (3)
Other (%)
pain 2 (5) - 8 (23) - - -5 (14)
fever 2 (5) 1 (3) 3 (9) - - - -
Figure 6 Median overall survival for global patients population
according to the number of TACE treatments delivered: 1TACE
treatment (—), 2 TACE treatments (———————) and ≥3
TACE treatments (.........) (74 vs 31 vs 27 months, p = 0.0029).
Figure 7 Median time to progression for global patients
population according to the number of TACE treatments
delivered: 1TACE treatment (—), 2TACE treatments
(——————) and ≥3 TACE treatments (.........) (p = 0.0042).
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than the sample size presented in the analog retrospec-
tive trial by Dhanasekaran et al.
The enrollment time itself (11 years in the study by
Dhanasekaran vs 7 years in our analysis) could have
influenced results as well, with the longer enrollment
time in the trials by Dhanasekaran possibly putting at
stake sample homogeneity.
Unfortunately the trial by Lencioni et al does not
include information about overall survival and time to
progression, but only data about response rate., which
resulted improved for pTACE. Nevertheless although
not significant in our study response rate for TACE and
pTACE are comparable to those reported by Lencioni,
thus suggesting an effective reproducibility of our results
in the clinical practice.
It is possible that pTACE with microspheres could
have a greater embolizant effect than TACE with lipio-
dol, and this would lead to increased tumor growth fac-
tors release in response to hypoxia, with consequently
probability of recurrence and reduced overall survival
and time to progression. The response rate, assessed at
one month after treatment, however, is similar between
the two groups, because these molecular mechanisms
would not be able to influence it, resulting in a statisti-
cally significant difference in such a short time. In this
setting treatment with sorafenib may represent a valu-
able asset to further improve clinical results.
Our analysis also showed a more pronounced treat-
ment benefit for older patients. This observation may be
related to either a more aggressive tumor behavior in
younger patients or a more indolent tumor progression
in older age (or to a combination of both considerations).
Many patients in our series received more sessions of
TACE or pTACE treatments during their medical his-
tory. These patients seem to have obtained an advantage
in terms of overall survival and time to progression
compared to those treated with a single TACE or
pTACE session. This seems to imply that certain biolo-
gical characteristics could make certain HCC more or
less responsive to treatment with TACE. These consid-
erations should of course be considerate merely
speculative.
Further studies focusing on biological and clinical
characteristics of HCC should be conducted before defi-
nitive conclusion could be drawn.
The observation that patients who received a sub-
median dose of drug may have an advantage in terms of
overall survival and time to progression compared to
those who received a dose over-the median deserves
further comments. It is possible that a higher dose of
chemotherapy would result in an additional damage to a
liver function already heavily compromised due to the
underlying disease, rather than an advantage, measurable
with a tumor shrinkage.
Another crucial point of discussion in HCC is the use
of a staging system which effectively reproducible.
In our study none of the staging systems commonly
used in clinical practice has proven to be able to classify
patients from a prognostic point of view, with the
exception of the Okuda system, which proved able to
influence the overall survival (p = 0.046).
Unlike most other malignancies, for which the staging
systems are well codified and universally accepted the
staging systems proposed for HCC are not universally
adopted and shared. One of the reasons that makes it
difficult to obtain reliable results, is related to the fact
that in most cases, the tumor occurs in patients with
liver cirrhosis. Therefore tumor stage, liver function and
clinical characteristics may differently concur to define
subgroups of HCC in different patients.
In this perspective, the results of our analysis proved
to agree with the majority of studies in the literature.
Conclusion
The clinical management of HCC is becoming increas-
ingly complex as therapeutic options are expanding. The
patient has, in most cases, two diseases, cancer and the
underlying liver disease that often heavily influenced, by
mechanisms not yet completely clear, the response to
cancer therapy and prognosis. So it is clear how crucial
is a multi-specialist management of patients with HCC.
In this framework, loco-regional treatment still plays
an important role and appears to be an essential point
of comparison even, and maybe even more, in the era of
biological therapies.
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